Latest Breaking News On - Blueprint for action national academy of sciences - Page 1 : comparemela.com

Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported that on August 18, 2023 the Board of Directors, including Yutaka Niihara, M.D., Ph.D, determined that Dr. Niihara would no longer serve as Chief Executive Officer of Emmaus, or as Chairman of the Board, in order to allow Dr. Niihara to pursue business opportunities in Ube, Japan and in India previously initiated by Emmaus. Dr. Niihara was the p

United statesUnited arab emiratesSaudi arabiaKingdom of saudi arabiaGeorge sekulichWillis leeExchange commission onSaudi food drug authorityCommittee on addressing sickle cell diseaseEmmaus life sciencesCenters for diseaseEmmaus life sciences incBlueprint for action national academy of sciencesNational center on birth defectsCompany contactDrug administration